Skip to main content

Advertisement

Table 3 Summary of the biomarkers that are significantly different between neurodegenerative disorders

From: Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

  Aβ1–42 T-tau T-tau/Aβ1–42 P-tau NFL AβX-42 AβX-42/X-40 APPα APPβ
AD vs DLB   + ++ + ++ + ++    + + +
AD vs bvFTD + ++ + ++ +++ + ++ + + ++ + ++ + ++ + ++
AD vs PNFA +   +   + ++     
AD vs SD + ++ + ++ + ++ + ++ + ++ + ++ + ++   
DLB vs bvFTD + ++   +    +    
DLB vs PNFA   +   + +    + +
DLB vs SD + ++   +   + + +   
bvFTD vs PNFA   + ++ + ++ +    + + ++ + ++
bvFTD vs SD          
PNFA vs SD + + + ++ +    +   
  1. Biomarkers with “+” distinguish between groups with p < 0.05 from the unadjusted analysis, and “++” distinguish between groups with Bonferroni corrected p < 0.003
  2. amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, bvFTD behavioural variant frontotemporal dementia, DLB dementia with Lewy bodies, PNFA progressive non-fluent aphasia, SD Semantic dementia, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau